On November 9, 2026, Compass Pathways said it had completed its application asking the FDA to approve a psilocybin medicine [1], and the news moves fast. This page tells you where things stand, what an approval would change, and what it would not. It was last checked on November 17, 2026, so check that date before you rely on it.
As of that date, the FDA has not approved a psilocybin drug [5] [15], and psilocybin and psilocyn remain Schedule I controlled substances under federal law [10]. Compass Pathways completed its application to the FDA on November 9, 2026 [1], and we found no FDA decision on it yet.
The short version
- No approval yet. Compass calls its psilocybin product, COMP360, "investigational" [1].
- One application confirmed, one reported. Compass completed its New Drug Application for treatment-resistant depression on November 9, 2026 [1]. A November 2 trade press report said Usona Institute had filed one for major depressive disorder. Usona declined to comment [13].
- The fast review is in question. Compass holds an FDA priority voucher meant to shorten review to one to two months [2]. On November 12, Reuters reported that the FDA had shelved the voucher program. The Department of Health and Human Services disputes that and says the pilot is ongoing [12].
- Approval is not legalization. Compass says its product must be rescheduled before it can be sold in the U.S. [1].
- Psilocybin, including in mushrooms, is still Schedule I under federal law [10].
Where the applications stand
Compass Pathways (COMP360, treatment-resistant depression). The FDA gave this program Breakthrough Therapy designation in 2018 [4], a status meant to speed development of drugs for serious conditions [14]. In April 2026 the FDA agreed to review the application in parts as they were ready, called a rolling review, and awarded a Commissioner's National Priority Voucher. Compass said the voucher aims for a review of one to two months after filing, "while maintaining FDA's rigorous safety and efficacy standards" [2]. On November 9, Compass said it had completed the application. It reported that two Phase 3 trials and an earlier Phase 2b study each met their main goal, across more than 1,000 participants [1]. These are the company's own statements.
Usona Institute (psilocybin, major depressive disorder). The FDA gave this program Breakthrough Therapy designation in 2019, and Usona has finished enrolling its Phase 3 study [5]. It received a priority voucher in April 2026 [6]. On November 2, Psychedelic Alpha reported that Usona had completed its application. Usona declined to comment, and its own site does not mention a filing [5] [13]. Usona says it does not offer expanded access [5].
The voucher program. In April 2026, the FDA said it was issuing priority vouchers to three companies studying psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone for PTSD [16]. According to Pharmacy Times, relaying Reuters, career scientists have resumed oversight of review timelines for the drugs still in the program. HHS says the pilot is ongoing [12].
What the federal government has done in 2026
- Executive order. Executive Order 14401, signed April 18, 2026, directs the FDA to give priority vouchers to appropriate psychedelic drugs with Breakthrough Therapy designation. It also tells the FDA and the Drug Enforcement Administration (DEA) to set up a way for eligible patients to reach psychedelic drugs, including ibogaine, under the federal Right to Try Act [7].
- Rescheduling. The same order directs the Attorney General, with the Department of Health and Human Services, to review products containing a Schedule I substance that complete Phase 3 trials for a serious mental health disorder, so that rescheduling, if appropriate, can move quickly for the specific products the FDA approves [7].
- Trial guidance. In July 2026 the FDA finalized its guidance for companies running psychedelic drug trials, first issued as a draft in June 2023 [8]. Guidance gives the FDA's nonbinding recommendations for developing these drugs and designing trials. It does not approve anything.
- Public hearing. On September 14, 2026, the FDA held a public hearing on the possible future therapeutic use of psychedelic drugs in supervised settings [9].
What an approval would and would not change
If the FDA approves COMP360, Compass expects to launch it in the first half of 2027 [1] [3]. Compass says the product must also be rescheduled first [1], and the executive order describes rescheduling for "specific products" the FDA approves, not psilocybin in general [7]. Psilocybin and psilocyn stay on the federal Schedule I list until that changes [10]. State laws are separate. Our law pages cover them state by state, starting with Montana.
Approval is not certain
A promising application can still be turned down. In August 2024, the FDA declined to approve Lykos Therapeutics' MDMA-assisted therapy for PTSD. Lykos said the FDA found it "could not be approved based on data submitted to date" and asked for another Phase 3 trial [11].
Common questions
Is psilocybin FDA approved?
Not as of November 17, 2026 [5] [15]. Compass completed its application on November 9 [1].
When could a psilocybin medicine be available?
Compass expects a launch in the first half of 2027, subject to FDA approval [1] [3], and says the product must be rescheduled first [1]. That is the company's forecast, not an FDA commitment, and the reported change to the voucher program could affect the timing [12].
Would approval make psilocybin mushrooms legal?
No. Psilocybin and psilocyn would stay Schedule I under federal law [10], and the executive order speaks of rescheduling specific products the FDA approves, not psilocybin in general [7].
Can I get psilocybin through Right to Try?
The executive order directs the FDA and the DEA to set up a Right to Try pathway for psychedelic drugs [7]. An order to build a pathway is not the pathway itself, so ask your doctor before relying on it.
Is the FDA guidance an approval?
No. The July 2026 guidance gives nonbinding recommendations for developing psychedelic drugs and designing trials [8].
Sources (16)
- Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression. Compass Pathways, 2026.
- Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher. Compass Pathways, 2026.
- Compass Pathways third quarter 2026 financial results. Compass Pathways (SEC filing), 2026.
- COMPASS Pathways receives FDA Breakthrough Therapy designation for psilocybin therapy for treatment-resistant depression. Compass Pathways, 2018.
- Psilocybin: drug development. Usona Institute, 2026.
- FDA grants priority vouchers to 3 psychedelic medications. Managed Healthcare Executive, 2026.
- Executive Order 14401, Accelerating Medical Treatments for Serious Mental Illness. Federal Register, 2026.
- Psychedelic Drugs: Considerations for Clinical Investigations (final guidance). U.S. Food and Drug Administration, 2026.
- Considerations for Potential Future Therapeutic Use of Psychedelic Drugs Public Hearing. U.S. Food and Drug Administration, 2026.
- 21 CFR 1308.11, Schedule I. Electronic Code of Federal Regulations, 2026.
- Lykos Therapeutics Announces Complete Response Letter for Midomafetamine Capsules for PTSD. Lykos Therapeutics, 2024.
- FDA Reportedly Shelves Commissioner's National Priority Voucher Program. Pharmacy Times, 2026.
- Usona Files Psilocybin for Depression NDA as Race With Compass Tightens. Psychedelic Alpha, 2026.
- Breakthrough Therapy. U.S. Food and Drug Administration, 2026.
- Novel Drug Approvals for 2026. U.S. Food and Drug Administration, 2026.
- FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order. U.S. Food and Drug Administration, 2026.